RxDoctor Payments Data

Bethany McDaniel-Vanderzwaag, MD

Family Medicine · Elkhart, INNPI 1639178650

Payments from drug & device makers

$664in general payments, 2019–2025

Across 35 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$119
  • AstraZeneca$69
  • Lilly USA, LLC$56
  • Boehringer Ingelheim$50
  • Pfizer$46
  • Otsuka America Pharmaceutical, Inc.$45
  • plus $279 from 12 others

What the payments were for

  • Food & beverage$64597%
  • Education$193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$664 in reported general payments places this provider in the 50th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$62,099
Medicare patients
109
Services billed
1,159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$75,359
JardianceEmpagliflozin45$55,535
TrulicityDulaglutide34$53,226
FarxigaDapagliflozin Propanediol19$26,520
RybelsusSemaglutide11$18,045
XareltoRivaroxaban13$16,869
MounjaroTirzepatide16$16,140
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$15,476
EliquisApixaban13$14,057
LinzessLinaclotide11$12,336
Aripiprazole22$11,159
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$11,137
JanuviaSitagliptin Phosphate14$8,961
MyrbetriqMirabegron15$7,283
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$5,996

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$18$93,40461 claims
Lilly USA, LLCTrulicity, Mounjaro$56$69,36650 claims
Boehringer IngelheimJardiance$50$55,53545 claims
AstraZenecaFarxiga$69$26,52019 claims
PfizerEliquis$46$14,05713 claims
AbbVieLinzess$119$12,33611 claims
Astellas Pharma US IncMyrbetriq$22$7,28315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Elkhart

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →